Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a …
T Yamada, M Wakabayashi, A Bhalla, N Chopra… - Cardiovascular …, 2021 - Springer
Background Emerging evidence suggests that sodium-glucose cotransporter-2 (SGLT-2)
inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with …
inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with …
Can metformin exert as an active drug on endothelial dysfunction in diabetic subjects?
T Salvatore, PC Pafundi, R Galiero, L Rinaldi… - Biomedicines, 2020 - mdpi.com
Cardiovascular mortality is a major cause of death among in type 2 diabetes (T2DM).
Endothelial dysfunction (ED) is a well-known important risk factor for the development of …
Endothelial dysfunction (ED) is a well-known important risk factor for the development of …
Modifiable risk factors in young adults with first myocardial infarction
S Yandrapalli, C Nabors, A Goyal, WS Aronow… - Journal of the American …, 2019 - jacc.org
Abstract Background: Modifiable risk factors (RFs) play an important role in the development
and prognosis of acute myocardial infarction (AMI). Objectives: This study sought to study …
and prognosis of acute myocardial infarction (AMI). Objectives: This study sought to study …
Wearable glucose monitoring and implantable drug delivery systems for diabetes management
The global cost of diabetes care exceeds 1trillioneachyearwithmorethan 327 billion being
spent in the United States alone. Despite some of the advances in diabetes care including …
spent in the United States alone. Despite some of the advances in diabetes care including …
Trends in first-line glucose-lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA
OBJECTIVE We evaluated recent use trends and predictors of first-line antidiabetes
treatment in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Using two …
treatment in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS Using two …
Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients …
S Tsukamoto, R Morita, T Yamada, S Urate… - Diabetes Research and …, 2022 - Elsevier
Aims Both sodium-glucose cotransporter-2 (SGLT-2) inhibitors and mineralocorticoid
receptor antagonists (MRAs) have been shown to reduce cardiovascular (CV) event in …
receptor antagonists (MRAs) have been shown to reduce cardiovascular (CV) event in …
Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease
Over the past 66 years, our knowledge of the role of the endothelium in the regulation of
cardiovascular function and dysfunction has advanced from the assumption that it is a single …
cardiovascular function and dysfunction has advanced from the assumption that it is a single …
Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress
SGLT2 inhibitors show promising cardio-protection in the diabetic populace. However, the
defending effect of SGLT2 inhibition in diabetes-associated cardiac complications and the …
defending effect of SGLT2 inhibition in diabetes-associated cardiac complications and the …
[HTML][HTML] Nutritional, phytochemical, antioxidant, α-glucosidase and α-amylase inhibitory properties of Moringa oleifera seeds
X Gu, Y Yang, Z Wang - South African Journal of Botany, 2020 - Elsevier
The aim of this study was to analyze nutritional characteristics of Moringa oleifera seed and
evaluate phytochemical compounds, as well as antioxidant and enzyme inhibitory activities …
evaluate phytochemical compounds, as well as antioxidant and enzyme inhibitory activities …
Adjuvant therapy with mushroom polysaccharides for diabetic complications
X Jiang, W Meng, L Li, Z Meng, D Wang - Frontiers in Pharmacology, 2020 - frontiersin.org
Background Diabetic complications seriously endanger the health of most diabetic patients
around the world. Most chemical hypoglycemic agents have adverse effects and are unable …
around the world. Most chemical hypoglycemic agents have adverse effects and are unable …